Navigation Links
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Date:12/12/2011

al tool for the development and commercialisation of RNAi therapeutics with enhanced efficacy and will continue to work to translate this value into our own RNAi therapeutic pipeline."

Silence Therapeutics is building and strengthening its global, diverse and competitive intellectual property portfolio. This provides the Company and its partners with a strong proprietary position in the RNAi therapeutics space. At present, Silence's global patent portfolio contains issued patents and pending applications covering strategic areas of RNAi therapeutic development. These include multiple proprietary siRNA delivery technologies, potent siRNA sequences specific for high-value disease targets and key RNAi sequence and chemical modifications.

Notes for editors                    

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry.

The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endo-thelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system e
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
2. Silence Therapeutics Provides Corporate and Development Update
3. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Ottawa, Ontario (PRWEB) November 27, 2014 ... Korean Ministry of Food and Drug Safety (MFDS) regulatory ... The system provides genetic results in less than 60 ... system is indicated as an aid for doctors to ... 2C19 genetic pathway. These include some of the world’s ...
(Date:11/26/2014)... 26, 2014 Publicis Healthcare Communications Group ... the organization has won a total of 20 awards ... LifeBrands was honored with a Silver Award and 11 ... eight Awards of Excellence. , The Annual Rx ... and promotion. The Awards provide a forum for the ...
(Date:11/26/2014)... In keeping with the holiday spirit, ... of last-minute Thanksgiving savings. The company is offering up ... product lines this holiday weekend as well as a ... and Cyber Monday are right around the corner, and ... loyal customers and those looking to explore their ancestry, ...
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
Breaking Biology Technology:Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3
... Mass., March 19 Biopure,Corporation (Nasdaq: ... Kingdom,s,Medicines and Healthcare products Regulatory Agency (MHRA) ... manufacturing facility. The,inspection report contained no "Critical" ... manufacturing practices. The MHRA report identified,shortcomings characterized ...
... 19 AdvanDx announced it received,Frost & ... Award in the,field of rapid in-vitro molecular ... on AdvanDx,s easy-to-use, molecular-based,PNA FISH(TM) diagnostics to ... days. The rapid PNA FISH results enable ...
... MacroChem,Corporation (OTC Bulletin Board: MACM) today announced ... of Chief Financial Officer, effective,immediately. Mr. Luci has ... Development since joining the Company in December,2007., ... Inc. prior to its,successful merger transaction with Genzyme ...
Cached Biology Technology:Biopure Completes U.K. Regulatory Agency Inspection 2AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 2AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 3AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 4MacroChem Appoints David P. Luci as New CFO 2MacroChem Appoints David P. Luci as New CFO 3
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
(Date:11/4/2014)... Think about the way our bodies are assembled during ... that they are supposed to become a nerve or ... the correct place and alignment? Researchers at the University ... In a new study, UM researchers describe the signaling ... neighbors, at the head-trunk region. Their discovery may have ...
(Date:11/4/2014)... A majority of Madagascar,s 101 species of lemurs are ... for the rainforests they call home. A new study ... can have on rainforest tree populations, which raises concerns ... the region,s rich biodiversity. , A large proportion of ... Lemurs in turn disperse the seeds of their ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... engineer has been awarded a $394,300 grant from the ... flow in the new facilities of the 150-mile Integrated ... of civil engineering, will investigate the best methods and ... effort to eliminate biological growths in the new pump ...
... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ...
... 10% of breast and ovarian cancers are familial in ... attributable to inherited mutations from the parents in genes ... mutations, PARP inhibitors, which are currently in clinical trials, ... option for personalised cancer treatment, an alternative to standard ...
Cached Biology News:UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
...
Biology Products: